CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 25 enrolled
Drug / intervention
cediranib maleate +2 moredrug
Likely dose
Cediranib maleate given PO (specific dose not stated)AI-extracted
Key inclusion· 6
  • ✓Histologically or cytologically confirmed small cell lung cancer
  • ✓Measurable disease: ≥20 mm (conventional) or ≥10 mm (spiral CT)
  • ✓Prior platinum-based chemotherapy required; no more than 1 prior chemotherapy regimen allowed
  • ✓Life expectancy >12 weeks
Key exclusion· 8
  • ✕Brain metastases excluded
  • ✕Chemotherapy, radiotherapy, or major surgery within 4 weeks (6 weeks for nitrosoureas or mitomycin C)
  • ✕Investigational agents or trials within 30 days
  • ✕QTc >500 msec or familial long QT syndrome

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00245063
NCT00245063Phase 2Completed
CompareCT.gov

Phase II Study of AZD2171 in Patients With Recurrent Small Cell Lung Cancer

National Cancer Institute (NCI)·interventional·Posted Oct 27, 2005·Updated Oct 2, 2014

In Brief

A Phase 2 clinical trial evaluating cediranib maleate, laboratory biomarker analysis, and 1 other intervention for Recurrent Non-small Cell Lung Cancer. Completed, enrolled 25 participants across 1 site.

Detailed Summary

This phase II trial is studying how well AZD2171 works in treating patients with recurrent small cell lung cancer. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Non-small Cell Lung Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 27, 2005
Enrollment StartMar 1, 2006
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 20.7 years ago

Interventions

cediranib maleatedrug

Given PO

laboratory biomarker analysisother

Correlative studies

pharmacogenomic studiesother

Optional correlative studies